Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Pauline CorbauxGilles FreyerOlivier GlehenBenoit YouNaoual BakrinAudrey GelotDavid DaydeChristophe SajousMax PiffouxJulien PéronGaelle LescuyerLéa PayenVahan KepenekianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer. Further investigation at 3 mg/kg is warranted.